Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Better Therapeutics, Inc. - Common Stock (NQ:BTTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Better Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Better Therapeutics to Participate in BTIG Digital Health Forum
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer
From Better Therapeutics, Inc.
Via Business Wire
Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Participate in Three Upcoming Investor Conferences
From Better Therapeutics
Via Business Wire
Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinical Cardiology
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Participate in Cowen’s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes Care
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 13, 2022
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Key Milestones and Updates for Ongoing Studies of its Digital Therapeutics Approach for Cardiometabolic Diseases
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Participate in Chardan’s Virtual Prescription Digital Therapeutics Summit
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Host Call Detailing Promising Results from Pivotal Clinical Trial for Type 2 Diabetes Digital Therapeutics
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Participate in Two Upcoming Investor Events
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy Officer
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors
From Better Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.